Drugs / ECT-001-CB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04594031 | Jul 2021 → Sep 2023 | hemopoietic proliferation, sickle cell disease | ExCellThera inc. | Withdrawn | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07301866 | Oct 2025 → Oct 2027 expected | acute leukemia, myelodysplastic syndrome | Ciusss de L'Est de l'Île de Montréal | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04990323 | Dec 2021 → Dec 2025 | myeloid hemopathy | ExCellThera inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04103879 | Nov 2020 → Feb 2026 | hematopoietic and lymphoid cell neoplasm | ExCellThera inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECT-001-CB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990323 ↗ |
| Modality | Cell therapy | “ECT-001-Expanded Cord Blood Transplant” NCT04990323 ↗ |
| Route | Other | “The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant.” NCT04990323 ↗ |